Synthesis and Characterization of Novel 2-Amino-Chromene-Nitriles that Target Bcl-2 in Acute Myeloid Leukemia Cell Lines

The anti-apoptotic protein Bcl-2 is a well-known and attractive therapeutic target for cancer. In the present study the solution-phase T3P-DMSO mediated efficient synthesis of 2-amino-chromene-3-carbonitriles from alcohols, malanonitrile and phenols is reported. These novel 2-amino-chromene-3-carbonitriles showed cytotoxicity in human acute myeloid leukemia (AML) cell lines. Compound 4g was found to be the most bioactive, decreasing growth and increasing apoptosis of AML cells. Moreover, compound 4g (at a concentration of 5 µM) increased the G2/M and sub-G1 (apoptosis) phases of AML cells. The AML cells treated with compound 4g exhibited decreased levels of Bcl-2 and increased levels of caspase-9. In silico molecular interaction analysis showed that compound 4g shared a similar global binding motif with navitoclax (another small molecule that binds Bcl-2), however compound 4g occupies a smaller volume within the P2 hot spot of Bcl-2. The intermolecular π-stacking interaction, direct electrostatic interactions, and docking energy predicted for 4g in complex with Bcl-2 suggest a strong affinity of the complex, rendering 4g as a promising Bcl-2 inhibitor for evaluation as a new anticancer agent.

[1]  Erinna F. Lee,et al.  Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.

[2]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[3]  Basappa,et al.  Novel Benzoxazine-Based Aglycones Block Glucose Uptake In Vivo by Inhibiting Glycosidases , 2014, PloS one.

[4]  Saul H Rosenberg,et al.  Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. , 2008, Journal of medicinal chemistry.

[5]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[6]  F. Badria,et al.  Synthesis and biological evaluation of certain alpha,beta-unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents. , 2000, Journal of medicinal chemistry.

[7]  J. Tamburini,et al.  Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[8]  H. Gourdeau,et al.  Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. , 2004, Molecular cancer therapeutics.

[9]  C. Xing,et al.  Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. , 2006, Journal of medicinal chemistry.

[10]  B. Bauvois,et al.  p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells. , 2013, Biochimica et biophysica acta.

[11]  Basappa,et al.  A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-α. , 2010, Cancer letters.

[12]  S. Mori,et al.  SOX7 is down-regulated in lung cancer , 2013, Journal of experimental & clinical cancer research : CR.

[13]  Duane D. Miller,et al.  Chromenes: potential new chemotherapeutic agents for cancer. , 2013, Future medicinal chemistry.

[14]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[15]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[16]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[17]  William E. Kemnitzer,et al.  Discovery of 4-aryl-2-oxo-2H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. , 2008, Bioorganic & medicinal chemistry letters.

[18]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[19]  P. Cartron,et al.  The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. , 2006, Cancer research.

[20]  Liu Liu,et al.  Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression. , 2012, Journal of medicinal chemistry.

[21]  Basappa,et al.  Solution-phase synthesis of novel delta2-isoxazoline libraries via 1,3-dipolar cycloaddition and their antifungal properties. , 2003, Bioorganic & medicinal chemistry.

[22]  Basappa,et al.  Synthesis and characterization of novel 1,2-oxazine-based small molecules that targets acetylcholinesterase. , 2014, Bioorganic & medicinal chemistry letters.

[23]  K. Schulze-Osthoff,et al.  Apoptosis-based therapies and drug targets , 2005, Cell Death and Differentiation.

[24]  S. Joos,et al.  The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.

[25]  William E. Kemnitzer,et al.  Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7,8-positions. , 2007, Journal of medicinal chemistry.

[26]  S. Jackson,et al.  Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function. , 2012, Blood.

[27]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[28]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[29]  N. Russell,et al.  The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells , 2010, Molecular Cancer Therapeutics.

[30]  P. Houghton,et al.  Anti-Tumor Activity of a Novel HS-Mimetic-Vascular Endothelial Growth Factor Binding Small Molecule , 2012, PloS one.

[31]  Yun Dai,et al.  The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. , 2004, Molecular cancer therapeutics.

[32]  Basappa,et al.  New cholinesterase inhibitors: Synthesis and structure-activity relationship studies of 1,2-benzisoxazole series and novel imidazolyl-d2-isoxazolines. , 2005 .

[33]  F. Badria,et al.  Synthesis and biological evaluation of certain α, β-unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents , 2000 .

[34]  S. Rogelj,et al.  Structural simplification of bioactive natural products with multicomponent synthesis. 2. antiproliferative and antitubulin activities of pyrano[3,2-c]pyridones and pyrano[3,2-c]quinolones. , 2008, Journal of medicinal chemistry.